<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01926288</url>
  </required_header>
  <id_info>
    <org_study_id>CTTQ805-4</org_study_id>
    <nct_id>NCT01926288</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Entecavir Maleate Tablets in Chinese Patients With Hepatitis B</brief_title>
  <official_title>Efficacy and Safety of Entecavir Maleate Tablets in Chinese Patients With Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of Entecavir maleate tablets
      in Chinese patients with hepatitis B
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compared with baseline, decline of serum HBV-DNA in the value</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">287</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>HBeAg positive group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Entecavir maleate tablets (1) + blank Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks .
Blank maleate entecavir tablets (1) + Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBeAg-negative group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Entecavir maleate tablets (1) + blank Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks .
Blank maleate entecavir tablets (1) + Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir maleate tablets</intervention_name>
    <arm_group_label>HBeAg positive group</arm_group_label>
    <arm_group_label>HBeAg-negative group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>blank Baraclude tablets</intervention_name>
    <arm_group_label>HBeAg positive group</arm_group_label>
    <arm_group_label>HBeAg-negative group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blank maleate entecavir tablets</intervention_name>
    <arm_group_label>HBeAg positive group</arm_group_label>
    <arm_group_label>HBeAg-negative group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baraclude tablets</intervention_name>
    <arm_group_label>HBeAg positive group</arm_group_label>
    <arm_group_label>HBeAg-negative group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects diagnosed of HBeAg positive or negative chronic hepatitis B

          2. Aged 18 to 70 years old，male or female

          3. Patients with previously HBsAg-positive, HBeAg-positive for 24 weeks, HBV-DNA&gt;
             105copies/ml. HBeAg-negative for 24 weeks or more, HBV-DNA&gt; 105 copies/ml.

          4. 1.3 times the upper normal limit (1.3 × ULN) ≤ alanine aminotransferase (ALT) ≤ 10 ×
             ULN.

          5. Total serum bilirubin (TBIL) ≤ 2.5 × ULN.

          6. Prothrombin activity (PTA) ≥ 60% or prothrombin time prolonged than normal ≤ 3
             seconds).

          7. WBC ≥ 3.5 × 109 / L, PLT ≥ 70 × 109 / L, serum albumin (ALB)≥ 35 g / L.

          8. Creatinine (Cr) ≤ 1.5 × ULN.

          9. If patients take intermittently with interferon, nucleoside (acid) analogues, α1
             thymosin before enrollment with 24 weeks, the time is no more than 12 weeks.

         10. Patients signed an informed consent form and compliance was good.

        Exclusion Criteria:

          1. Patients were infected with other viruses as HAV, HCV, HDV, HEV, CMV, EBV, HIV etc.

          2. Patients with cirrhosis or liver cancer.

          3. Patients have participated in another therapeutic clinical trial in 3 months.

          4. Granulocyte count &lt;1.5 × 109 / L, hemoglobin (HB)&lt;100g / L, sera
             alpha-fetoprotein(AFP)&gt; 100μg / L, patients' B ultrasonography pointed space-occupying
             lesions.

          5. Patients with severe heart, kidney, endocrine hematopoietic system and
             neuropsychiatric diseases.

          6. Patients with metabolic or autoimmune diseases such as systemic lupus erythematosus.

          7. Pregnant woman, lactating women or those who wre allergic for study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu Yan yan, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Infectious Diseases,Peking University First Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shi Guang feng, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xie Qing, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Jiaotong University Affiliated Ruijin Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tang Hong, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhang Da zhi, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Second Affiliated Hospital of Chongqing Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mao Qing, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital Of The Third Mililary Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ning Qin, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tongji Medical College of Hust Tongji Medical College Huazhong University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Li Jun, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheng Ji fang, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cheng Xin fang, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing You An Hospital,Capital Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Infectious Diseases,Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing You An Hospital,Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100054</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Of The Third Mililary Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Medical College of Hust Tongji Medical College Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Jiaotong University Affiliated Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital Of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Sichuan</state>
        <zip>400010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital Of Sichuan University</name>
      <address>
        <city>Chongqing</city>
        <state>Sichuan</state>
        <zip>400010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2013</study_first_submitted>
  <study_first_submitted_qc>August 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2013</study_first_posted>
  <last_update_submitted>December 27, 2017</last_update_submitted>
  <last_update_submitted_qc>December 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

